The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis

Ma, Guangzhi; Deng, Yunfu; Jiang, Hai; Wen, Li; Wu, Qiang; Zhou, Qinghua

doi:10.1016/j.cca.2018.03.038

Cited by 34 publications

(39 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 16 , 17 A meta-analysis of PD-L1 expression and prognosis of NSCLC patients suggested that PD-L1 expression was a prognostic factor related to poor survival. 18 However, in their study, Aguiar et al reported that PD-L1 expression was related to better progression-free survival (HR: 0.69, 95% CI: 0.57–0.85) and better overall survival (HR: 0.77, 95% CI: 0.67–0.89). 19 Possible explanations for these indeterminate observations may be discrepancy in study design such as biomarker requirements (cut-off value, tumor heterogeneity, the inclusion of tumor stromal cells), length of the follow-up period and sample size.…”

Section: Discussionmentioning

confidence: 91%

PD-L1 in Lung Adenocarcinoma: Insights into the Role of 18F-FDG PET/CT

Cui¹,

Li²,

Du³

et al. 2020

CMAR

View full text Add to dashboard Cite

Purpose This study aimed to evaluate the role of 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET)/computed tomography (CT) in expression of tumor programmed death ligand-1 (PD-L1) expression and prognostic significance of 18 F-FDG PET/CT at different PD-L1 status in patients with lung adenocarcinoma. Patients and Methods Seventy-three patients with primary lung adenocarcinoma who received 18 F-FDG PET/CT before treatment were retrospectively included in this study. Expression of tumor PD-L1, programmed death-1 (PD-1) and glucose metabolic parameters were evaluated. Results Tumor PD-L1 expression was positively correlated with maximum standardized uptake value (SUVmax), total lesion glycolysis (TLG), hexokinase II (HK-II) and glucose transporter 1 (GLUT-1) ( P <0.0001 for all). SUVmax was a unique independent predictor of tumor PD-L1 expression, with an optimal cut-off value of 9.5. For all the patients, tumor stage ( P< 0.001) and SUVmax ( P =0.009) were independent prognostic indicators of disease-free survival (DFS)/progression-free survival (PFS) while carcino-embryonic antigen (CEA) ( P =0.003), Ki67 ( P =0.042), PD-L1 ( P =0.048) and TLG ( P =0.004) were independent prognostic indicators of overall survival (OS). Tumor stage ( P =0.004) and SUVmax ( P =0.022) were independent prognostic indicators of DFS/PFS while TLG ( P =0.012) and CEA ( P =0.045) were independent prognostic indicators of OS in the PD-L1-positive group. In the PD-L1-negative group, tumor stage ( P =0.002) and CEA ( P =0.006) were unique independent prognostic indicators of DFS/PFS and OS, respectively. Conclusion 18 F-FDG PET/CT may potentially predict tumor PD-L1 expression and play a role in predicting prognosis of PD-L1/PD-1 immunotherapy in lung adenocarcinoma.

show abstract

Section: Discussionmentioning

confidence: 91%

PD-L1 in Lung Adenocarcinoma: Insights into the Role of 18F-FDG PET/CT

Cui¹,

Li²,

Du³

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…Recent studies have evaluated the prognostic effect of PD‐L1 expression in NSCLC . However, the prognostic relevance of PD‐L1 expression in NSCLC remains controversial.…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies have evaluated the prognostic effect of PD-L1 expression in NSCLC. [27][28][29] However, the prognostic relevance of PD-L1 expression in NSCLC remains controversial. In our study, univariate and multivariate survival analysis showed that patients with a PD-L1 TPS ≥ 50% showed significantly poorer DFS and OS compared to those with a PD-L1 TPS < 50%.…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of ≥ 50% PD‐L1 expression with the SP263 monoclonal antibody in non‐small cell lung cancer patients

Song

Guo

et al. 2018

Thoracic Cancer

View full text Add to dashboard Cite

Background PD‐L1 expression in tumor cells has been associated with the efficacy of immune checkpoint inhibitors in non‐small cell lung cancer (NSCLC). The aim of this study was to explore correlations between smoking, genetic profiles, patient outcomes, and PD‐L1 expression in NSCLC. Methods PD‐L1 expression was evaluated in 241 surgically resected specimens by immunostaining and 50% was set as the cutoff value. Results Of the 241 tumors analyzed, a PD‐L1 tumor proportion score (TPS) of ≥ 50% was detected in 35 cases (14.5%) and a TPS of < 50% in 206 cases (85.5%). A PD‐L1 TPS ≥ 50% was significantly associated with smoking and EGFR wild‐type status ( P < 0.001 and P = 0.039, respectively). Detailed assessment of smoking variables showed that total smoking duration was a predictor of a PD‐L1 TPS ≥ 50% ( P = 0.001). Univariate and multivariate survival analyses revealed that patients with a PD‐L1 TPS ≥ 50% had poorer disease‐free and overall survival than those with a PD‐L1 TPS < 50% ( P = 0.001 and P < 0.001, respectively). Conclusion The incidence of a PD‐L1 TPS ≥ 50% was significantly higher in smoking and EGFR wild‐type NSCLC patients, particularly in long‐term smokers. A PD‐L1 TPS of ≥ 50% was an independent adverse prognostic factor for survival in patients with NSCLC.

show abstract

“…The programmed deathligand 1 (PD-L1)/programmed cell death-1 (PD-1) axis is an immunosuppressive pathway that facilitates immune escape of tumor cells (4). PD-L1 expression has been shown to be a prognostic marker of prognosis in various cancers, including lung cancer, esophageal squamous cell carcinoma, pancreatic cancer, and colorectal cancer (5)(6)(7)(8). Many studies have also explored the prognostic value of PD-L1 in EC, with conflicting results (9)(10)(11)(12)(13)(14)(15)(16)(17).…”

Section: Introductionmentioning

confidence: 99%

Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis

Lü¹,

Li²,

Luo³

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Background: A series of studies have explored the prognostic value of programmed death-ligand 1 (PD-L1) in patients with endometrial cancer (EC); however, the results are controversial. Therefore, this meta-analysis was performed to estimate the associations between PD-L1 expression and the prognosis and clinicopathological features of EC. Methods: A comprehensive literature search of PubMed, Web of Science, and Embase was conducted up until September 06, 2019. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS) were computed using the random-effects model (REM) or fixed-effects model (FEM). Odds ratios (ORs) and 95% CIs were calculated to evaluate the relationship between PD-L1 and clinicopathological factors. Results: A total of 9 studies with 1,615 patients were included in the meta-analysis. The combined data showed that high expression of PD-L1 was not significantly correlated with OS (HR = 1.20, 95% CI = 0.41-3.52, p = 0.737) or PFS (HR = 1.12, 95% CI = 0.50-2.54, p = 0.778) in EC. In addition, PD-L1 expression was significantly associated with poor differentiation (OR = 2.82, 95% CI = 1.96-4.06, P < 0.001) and advanced stage (OR = 1.71, 95% CI = 1.12-2.60, p = 0.013). Conclusion: This meta-analysis suggests that PD-L1 expression is not associated with poor prognosis in patients with EC. However, PD-L1 expression is positively correlated with poor differentiation and advanced tumor stage in EC.

show abstract

The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis

Cited by 34 publications

References 54 publications

<p>PD-L1 in Lung Adenocarcinoma: Insights into the Role of <sup>18</sup>F-FDG PET/CT</p>

<p>PD-L1 in Lung Adenocarcinoma: Insights into the Role of <sup>18</sup>F-FDG PET/CT</p>

Clinical significance of ≥ 50% PD‐L1 expression with the SP263 monoclonal antibody in non‐small cell lung cancer patients

Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis

Contact Info

Product

Resources

About